Search Results - "Micol, Jean Baptiste"
-
1
Therapy-related myelodysplastic syndromes in the genomics era
Published in Bulletin du cancer (01-11-2023)“…Therapy-related myelodysplastic syndromes (t-MDS) represent a heterogeneous group of malignancies that arise as a late complication of prior exposure to…”
Get full text
Journal Article -
2
Bone marrow metastases mimicking acute leukaemia
Published in British journal of haematology (01-12-2019)Get full text
Journal Article -
3
The Role of Additional Sex Combs-Like Proteins in Cancer
Published in Cold Spring Harbor perspectives in medicine (01-10-2016)“…Additional sex combs-like (ASXL) proteins are mammalian homologs of Addition of sex combs (Asx), a protein that regulates the balance of trithorax and Polycomb…”
Get full text
Journal Article -
4
Comprehensive mutational profiling of core binding factor acute myeloid leukemia
Published in Blood (19-05-2016)“…Acute myeloid leukemia (AML) with t(8;21) or inv(16) have been recognized as unique entities within AML and are usually reported together as core binding…”
Get full text
Journal Article -
5
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
Published in Cancer cell (11-05-2015)“…Mutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic syndromes (MDS), but their role in MDS pathogenesis…”
Get full text
Journal Article -
6
Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis
Published in Nature (London) (01-10-2019)“…Transcription and pre-mRNA splicing are key steps in the control of gene expression and mutations in genes regulating each of these processes are common in…”
Get full text
Journal Article -
7
Loss of BAP1 function leads to EZH2-dependent transformation
Published in Nature medicine (01-11-2015)“…BAP1 regulation of EZH2 provides therapeutic opportunities in cancer. The tumor suppressors BAP1 and ASXL1 interact to form a polycomb deubiquitinase complex…”
Get full text
Journal Article -
8
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia
Published in Blood (12-07-2018)“…Mutations in receptor tyrosine kinase/RAS signaling pathway genes are frequent in core-binding factor (CBF) acute myeloid leukemias (AMLs), but their…”
Get full text
Journal Article -
9
Acute Abdominal Complications in Deeply Neutropenic Onco-Hematology Patients: A Retrospective Series of 105 Cases
Published in World journal of surgery (01-10-2022)“…Background Acute abdominal complications (AAC) in patients with deep neutropenia (DN) is challenging to manage because of the expected influence of AAC on…”
Get full text
Journal Article -
10
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Published in Nature communications (18-05-2017)“…Additional sex combs-like (ASXL) proteins are mammalian homologues of additional sex combs (Asx), a regulator of trithorax and polycomb function in Drosophila…”
Get full text
Journal Article -
11
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms
Published in Leukemia (01-01-2022)“…The germline predisposition associated with the autosomal dominant inheritance of the 14q32 duplication implicating ATG2B/GSKIP genes is characterized by a…”
Get full text
Journal Article -
12
Serum 2-Hydroxyglutarate Production in IDH1- and IDH2-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group
Published in Journal of clinical oncology (01-02-2014)“…Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML),…”
Get full text
Journal Article -
13
Myeloid malignancies with translocation t(4;12)(q11‐13;p13): molecular landscape, clonal hierarchy and clinical outcomes
Published in Journal of cellular and molecular medicine (01-10-2021)“…Translocation t(4;12)(q11‐13;p13) is a recurrent but very rare chromosomal aberration in acute myeloid leukaemia (AML) resulting in the non‐constant expression…”
Get full text
Journal Article -
14
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations
Published in Leukemia (01-09-2018)Get full text
Journal Article -
15
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations
Published in Haematologica (Roma) (01-02-2014)Get full text
Journal Article -
16
Disappearance of slan-positive non-classical monocytes for diagnosis of chronic myelomonocytic leukemia with an associated inflammatory state
Published in Haematologica (Roma) (01-04-2020)Get full text
Journal Article -
17
Impact and consequences of intensive chemotherapy on intestinal barrier and microbiota in acute myeloid leukemia: the role of mucosal strengthening
Published in Gut microbes (09-11-2020)“…Induction chemotherapy (7 + 3 regimen) remains the gold standard for patients with acute myeloid leukemia (AML) but is responsible for gut damage leading to…”
Get full text
Journal Article -
18
JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation
Published in Blood (25-09-2014)“…Megakaryopoiesis is a 2-step differentiation process, regulated by thrombopoietin (TPO), on binding to its cognate receptor myeloproliferative leukemia (MPL)…”
Get full text
Journal Article -
19
An atypical promyelocytic sarcoma and pleural effusion in a patient with Gorham's disease: Efficiency of ATRA/ATO‐based treatment
Published in Clinical case reports (01-08-2023)“…Key Clinical Message This is the first case of a promyelocytic sarcoma diagnosed on pleural effusion and exposed the difficulty of demonstrating a leukemic…”
Get full text
Journal Article -
20
Molecular Landscape of Therapy‐related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers
Published in HemaSphere (01-09-2021)“…Definition of therapy‐related myeloid neoplasms (TRMN) is only based on clinical history of exposure to leukemogenic therapy. No specific molecular…”
Get full text
Journal Article